Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts
(2023) In Cancer Treatment Reviews 112.- Abstract
- Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and the latter a locally aggressive behavior. Although usually not life-threatening, TGCT may cause chronic pain and adversely impact function and quality of life (QoL). CSFR1 inhibitors are effective with benefit on symptoms and QoL but are not available in most countries. The degree of uncertainty in selecting the most appropriate therapy and the lack of guidelines on the clinical management of TGCT make the adoption of new treatments inconsistent across the world, with suboptimal outcomes for patients. A... (More)
- Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and the latter a locally aggressive behavior. Although usually not life-threatening, TGCT may cause chronic pain and adversely impact function and quality of life (QoL). CSFR1 inhibitors are effective with benefit on symptoms and QoL but are not available in most countries. The degree of uncertainty in selecting the most appropriate therapy and the lack of guidelines on the clinical management of TGCT make the adoption of new treatments inconsistent across the world, with suboptimal outcomes for patients. A global consensus meeting was organized in June 2022, involving experts from several disciplines and patient representatives from SPAGN to define the best evidence-based practice for the optimal approach to TGCT and generate the recommendations presented herein. © 2022 The Author(s) (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1328f38c-a3f8-473d-959d-7001f41c80d7
- author
- Stacchiotti, Silvia ; Eriksson, Mikael and Bauer, Sebastian
- author collaboration
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- consensus, giant cell tumor of tendon sheath, human, pathology, quality of life, Consensus, Giant Cell Tumor of Tendon Sheath, Humans, Quality of Life
- in
- Cancer Treatment Reviews
- volume
- 112
- article number
- 102491
- publisher
- Elsevier
- external identifiers
-
- scopus:85145424768
- pmid:36502615
- ISSN
- 0305-7372
- DOI
- 10.1016/j.ctrv.2022.102491
- language
- English
- LU publication?
- no
- id
- 1328f38c-a3f8-473d-959d-7001f41c80d7
- date added to LUP
- 2023-01-16 11:28:59
- date last changed
- 2023-01-17 03:00:21
@article{1328f38c-a3f8-473d-959d-7001f41c80d7, abstract = {{Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and the latter a locally aggressive behavior. Although usually not life-threatening, TGCT may cause chronic pain and adversely impact function and quality of life (QoL). CSFR1 inhibitors are effective with benefit on symptoms and QoL but are not available in most countries. The degree of uncertainty in selecting the most appropriate therapy and the lack of guidelines on the clinical management of TGCT make the adoption of new treatments inconsistent across the world, with suboptimal outcomes for patients. A global consensus meeting was organized in June 2022, involving experts from several disciplines and patient representatives from SPAGN to define the best evidence-based practice for the optimal approach to TGCT and generate the recommendations presented herein. © 2022 The Author(s)}}, author = {{Stacchiotti, Silvia and Eriksson, Mikael and Bauer, Sebastian}}, issn = {{0305-7372}}, keywords = {{consensus; giant cell tumor of tendon sheath; human; pathology; quality of life; Consensus; Giant Cell Tumor of Tendon Sheath; Humans; Quality of Life}}, language = {{eng}}, publisher = {{Elsevier}}, series = {{Cancer Treatment Reviews}}, title = {{Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts}}, url = {{http://dx.doi.org/10.1016/j.ctrv.2022.102491}}, doi = {{10.1016/j.ctrv.2022.102491}}, volume = {{112}}, year = {{2023}}, }